{ "schema_version": 1, "kind": "condition", "id": "prostate-symptoms", "name": "Prostate Symptoms (Prostatism / LUTS)", "category": "acute", "sources": "Egyptian National Drug Formulary - cardiovascular.pdf, Tamsulosin monograph (chapter PDF p21) · Egyptian National Drug Formulary - endocrine.pdf, Finasteride monograph (chapter PDF p16) · Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. NBK558920.", "review_status": "reviewed", "verified_against": "Egyptian National Drug Formulary - cardiovascular.pdf, Tamsulosin monograph (chapter PDF p21) · Egyptian National Drug Formulary - endocrine.pdf, Finasteride monograph (chapter PDF p16) · Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. NBK558920.", "verified_date": "2026-08", "treatments": [ { "id": 1543, "generic": "Tamsulosin", "line": 1, "is_adjunct": false, "form": "oral.solid", "strength_mg": null, "adult_dose": "0.4 mg once daily (modified-release capsule)", "adult_duration": null, "dose_source": "Egyptian National Drug Formulary - cardiovascular.pdf, Tamsulosin monograph (chapter PDF p21)", "rationale": "Alpha-blocker first-line for symptomatic relief of benign prostatic obstruction; works faster than finasteride, so a reasonable first choice for a Cairo GP.", "cautions": [ "Postural (orthostatic) hypotension can occur, especially with the first dose.", "Floppy iris syndrome can occur during cataract surgery - inform the ophthalmologist that the patient is taking tamsulosin.", "Caution when combined with other antihypertensive or PDE5-inhibitor drugs (additive hypotension).", "Not indicated for hypertension itself (formulary note)", "RED FLAG - Inability to pass urine (acute retention), blood in the urine, back pain or weight loss suggesting prostate cancer, or a very high or rapidly rising PSA.", "Take extra care where there is a history of micturition syncope or of postural hypotension, and where a potent CYP3A4 inhibitor (eg, Itraconazole, Ketoconazole) is being used concurrently." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Not applicable - not indicated in children.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "NORMIRAMA 0.4 MG 30 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EGPI > RAMAPHARMA", "price_egp": 60.0, "pack_count": 30, "unit_price": 2.0, "strength_mg": 0.4, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "TAMSUNORM S.R. 0.4MG 30 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "RAMEDA", "price_egp": 60.0, "pack_count": 30, "unit_price": 2.0, "strength_mg": 0.4, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "TAMSULOSIN 0.4 MG 20 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "GLAXO SMITHKLINE > SANDOZ", "price_egp": 42.0, "pack_count": 20, "unit_price": 2.1, "strength_mg": 0.4, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "CUREPRO XR 0.4 MG 30 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "DEBEIKY > KHUFU PHARMA", "price_egp": 105.0, "pack_count": 30, "unit_price": 3.5, "strength_mg": 0.4, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "BLOCK ALPHA 0.4 MG MR 30 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ADWIA", "price_egp": 120.0, "pack_count": 30, "unit_price": 4.0, "strength_mg": 0.4, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "FIRAMAZIN 0.4MG 30 H.G.CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EVA PHARMA", "price_egp": 54.0, "pack_count": null, "unit_price": null, "strength_mg": 0.4, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "OMNIC 0.4MG 30 MODIFIED RELEASE CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ASTELLAS PHARMA > MULTIPHARMA", "price_egp": 147.0, "pack_count": null, "unit_price": null, "strength_mg": 0.4, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "OMNIC OCAS 0.4 MG 30 PROLONGED RELEASE F.C.TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ASTELLAS PHARMA INC > MULTIPHARMA", "price_egp": 282.0, "pack_count": null, "unit_price": null, "strength_mg": 0.4, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "prostate-symptoms" }, { "id": 1544, "generic": "Finasteride", "line": 2, "is_adjunct": false, "form": "oral.solid", "strength_mg": null, "adult_dose": "5 mg orally once daily, alone or combined with an alpha-1 blocker", "adult_duration": "6 to 12 months usually needed to see improvement", "dose_source": "Egyptian National Drug Formulary - endocrine.pdf, Finasteride monograph (chapter PDF p16)", "rationale": "Used alone or added to an alpha-blocker for larger prostates or an inadequate response to tamsulosin alone; formulary explicitly supports benign prostatic hyperplasia as an indication.", "cautions": [ "Pregnant women or women who may become pregnant must not handle crushed or broken tablets (teratogenic risk to a male fetus).", "Lowers PSA by roughly half after long-term use - interpret PSA results with this in mind and re-double any value when screening for prostate cancer.", "Reduced libido and erectile dysfunction are recognised side effects.", "Mood alterations including depressed mood, depression, and, less frequently, suicidal ideation has been reported. Monitor carefully.", "Prostate cancer: When compared to placebo, 5-alpha-reductase inhibitors (5-ARIs) have been associated with an increase in the incidence of high-grade prostate cancers.", "Diminished urinary flow: Carefully monitor patients with a large residual urinary volume or severely diminished urinary flow for obstructive uropathy; these patients may not be candidates for finasteride therapy.", "Finasteride has a slow onset (months) and does not help acute urinary retention." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Not indicated for use in women or children (formulary note).", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "PROHAIR 1 MG 30 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA", "price_egp": 24.0, "pack_count": 30, "unit_price": 0.8, "strength_mg": 1.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "NOPECIA 1 MG 30 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ADWIA", "price_egp": 36.0, "pack_count": 30, "unit_price": 1.2, "strength_mg": 1.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "MIXOSTERIDE 5 MG 14 F.C. TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA > PHARMA MIX", "price_egp": 30.0, "pack_count": 14, "unit_price": 2.14, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "PROSTAT 5MG 14 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "CID > OCTOBER PHARMA", "price_egp": 46.0, "pack_count": 14, "unit_price": 3.29, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "PROSTEC 5 MG 14 F.C.TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA", "price_egp": 47.0, "pack_count": 14, "unit_price": 3.36, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "FINASTURA 5MG 30 F.C.TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "GLOBAL NAPI PHARMACEUTICALS", "price_egp": 111.0, "pack_count": 30, "unit_price": 3.7, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "PROSTRIDE 5MG 30 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ADWIA", "price_egp": 183.0, "pack_count": 30, "unit_price": 6.1, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "PROSCAR 5MG 28 F.C. TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MERCK SHARP & DOHME > MERCK SHARP & DOHME SCIENTIFIC OFFICE", "price_egp": 258.0, "pack_count": 28, "unit_price": 9.21, "strength_mg": 5.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "prostate-symptoms" } ] }